• Pfizer's meningococcal vaccine candidate clears regulatory step

    The FDA accepted Pfizer's biologics license application for its pentavalent meningococcal vaccine candidate intended for people between the ages of 10 and 25. 
  • 6 nitrosamine drug recalls in 2022

    Since 2019, the FDA has reported dozens of drug recalls because of the presence of nitrosamine, a probable carcinogen that largely pulls blood pressure treatments off the market. 
  • FDA tentatively approves multiple sclerosis drug

    India-based drugmaker Aurobindo Pharma received a tentative approval from the FDA for its dimethyl fumarate capsules to treat multiple sclerosis, CNBC reported Dec. 27. 
  • 50 drugs on Mark Cuban's pharmacy with biggest cost reductions

    Nearly a year after launching the online pharmacy Mark Cuban Cost Plus Drug Co., the company has hundreds of generics, more than 1 million customers, and partnerships with pharmacy benefit managers and payers. 
  • Congress passes bill with multiple drug supply provisions: 4 notes

    Congress passed an end-of-year bill Dec. 23 that includes withdrawing a federal barrier to pharmacists prescribing an opioid overdose treatment and numerous strategies to manage persistent drug supply problems. 
  • Will Plan B One-Step pill cause an abortion? FDA says 'no'

    The so-called morning after pill, Plan B One-Step (and generic versions of the drug, levonorgestrel), does not cause abortions, the FDA confirmed Dec. 23, despite packaging information that suggests otherwise.
  • New HIV drug approved by FDA for adults with few treatment options 

    Sunlenca, a new HIV drug for patients with limited available treatment options, was approved Dec. 22 by the FDA. The new drug is an option for adults with HIV who cannot tolerate, are resistant to or have safety issues with other established treatments for the disease.
  • 'This won't be over in a week or 2': Wisconsin hospitals, pharmacies ration Tamiflu

    Wisconsin hospitals and pharmacies are limiting their Tamiflu prescriptions in the face of severe shortages, NBC affiliate WMTV reported Dec. 20.
  • 3rd death tied to Alzheimer's experimental drug trial

    A third death has been tied to experimental Alzheimer's drug lecanemab, amplifying concerns about its safety, Science reported Dec. 21.
  • Monoclonal drug wins approval after FDA revoked Eli Lilly's COVID-19 drug 

    The FDA approved Roche's monoclonal antibody to treat COVID-19 Dec. 21, about three weeks after the agency reversed its authorization for Eli Lilly's monoclonal drug. 
  • 10 systems seeking pharmacy leaders

    The following 10 hospitals, health systems and hospital operators have posted job listings seeking pharmacy leaders in the last week.
  • The loopholes of the 340B program

    Hospitals are failing to fulfill the promise of the 340B program, which offers discounted drugs to hospitals that treat a large proportion of underinsured and uninsured patients, The Wall Street Journal reported Dec. 20. 
  • HHS boosts Tamiflu access amid generic shortage

    As demand for a popular flu drug increases during the worst flu season in more than a decade, HHS expanded access to Tamiflu on Dec. 21 through the Strategic National Stockpile. 
  • Paxlovid worth 80% less, healthcare market research group says

    As drugmakers prepare for the government to stop paying for their COVID-19 treatments, the value of Pfizer's popular COVID-19 drug Paxlovid has decreased by more than 80 percent, according to the Institute for Clinical and Economic Review. 
  • Walgreens in 2022: A timeline of key events

    From its plan to acquire Summit Health to its robot-powered fulfillment centers, and from its $5 billion settlement for opioid cases to reforming its worker evaluation practices, here are Walgreens' biggest moves in 2022 listed in order of Becker's coverage. 
  • Former Merck, Eli Lilly leader moves to Moderna

    Chantal Friebertshäuser, a former executive at Merck and Eli Lilly, will join Moderna as the senior vice president of commercial, Europe, Middle East and Canada, effective Jan. 1. 
  • Federal program to reimburse pharmacists as providers

    Pharmacists will be listed as providers on some U.S. government employees' insurance bills for their roles in assessing COVID-19 symptoms and prescribing the antiviral Paxlovid. 
  • CVS, Walgreens limit sales of children's pain meds amid shortage

    The two largest pharmacy retailers are restricting orders for some pediatric pain medications as healthcare battles a strong season of flu, respiratory syncytial virus and COVID-19 cases, The Hill reported Dec. 19. 
  • TruePill wrongly dispensed thousands of stimulants, DEA says

    The Drug Enforcement Administration may revoke TruePill's ability to fill controlled substances over allegations that it wrongly filled thousands of prescriptions for stimulants used to treat attention-deficit/hyperactivity disorder. 
  • Eli Lilly's diabetes drugs in short supply: FDA

    The FDA added Eli Lilly's diabetes drugs Mounjaro and Trulicity to its list of medications in short supply Dec. 15. 

Featured Whitepapers

Featured Webinars